Technical Analysis for GRTS - Gritstone Oncology, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bearish Engulfing | Bearish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -8.21% | |
Wide Bands | Range Expansion | -8.21% | |
Gapped Up | Strength | -8.21% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.77% | |
Wide Bands | Range Expansion | -0.77% | |
Down 3 Days in a Row | Weakness | -0.77% | |
Wide Bands | Range Expansion | -4.46% |
Alert | Time |
---|---|
Down 1 ATR | about 16 hours ago |
Outside Day | about 18 hours ago |
Down 5% | about 18 hours ago |
Fell Below Previous Day's Low | about 18 hours ago |
Fell Below 10 DMA | about 18 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient’s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients’ TSNA to drive the patient’s immune system to attack and destroy tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Oncology Tumor Cancer Immunotherapy Machine Learning Virotherapy Immunotherapies Biopsy Tumor Cell
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.33 |
52 Week Low | 1.14 |
Average Volume | 1,844,598 |
200-Day Moving Average | 2.02 |
50-Day Moving Average | 2.45 |
20-Day Moving Average | 2.48 |
10-Day Moving Average | 2.65 |
Average True Range | 0.26 |
RSI (14) | 51.46 |
ADX | 21.17 |
+DI | 24.94 |
-DI | 18.69 |
Chandelier Exit (Long, 3 ATRs) | 2.31 |
Chandelier Exit (Short, 3 ATRs) | 2.64 |
Upper Bollinger Bands | 2.97 |
Lower Bollinger Band | 1.99 |
Percent B (%b) | 0.59 |
BandWidth | 39.58 |
MACD Line | 0.09 |
MACD Signal Line | 0.08 |
MACD Histogram | 0.0125 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.20 | ||||
Resistance 3 (R3) | 3.25 | 3.10 | 3.10 | ||
Resistance 2 (R2) | 3.10 | 2.94 | 3.07 | 3.06 | |
Resistance 1 (R1) | 2.83 | 2.84 | 2.76 | 2.78 | 3.02 |
Pivot Point | 2.68 | 2.68 | 2.64 | 2.65 | 2.68 |
Support 1 (S1) | 2.41 | 2.52 | 2.34 | 2.36 | 2.12 |
Support 2 (S2) | 2.26 | 2.42 | 2.23 | 2.08 | |
Support 3 (S3) | 1.99 | 2.26 | 2.05 | ||
Support 4 (S4) | 1.94 |